SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?

Detalhes bibliográficos
Autor(a) principal: Reuben, Rine Christopher
Data de Publicação: 2021
Outros Autores: Adogo, Lillian Yami
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista de Saúde Pública
Texto Completo: https://www.revistas.usp.br/rsp/article/view/192294
Resumo: The coronavirus disease 2019 (COVID-19) pandemic is significantly causing unprecedented clinical, socioeconomic, and public health challenges globally. The successful global administration of effective, safe and sustainable vaccine(s) is widely believed to be crucial in mitigating as well as preventing COVID-19. However, the rising cases of severe adverse events following immunization (AEFI) with COVID-19 vaccines including thrombosis, thrombocytopenia, and in some instances, death have created serious global concerns and could enormously contribute to vaccine hesitancy. Although the complete underlying pathophysiology and immunopathology of the COVID-19 vaccines related to AEFI, including thrombosis and/or anaphylaxis, are yet to be determined, exploring possible immuno-hypersensitivity could be crucial in the mechanisms associated with these reactions, thereby mitigating their occurrences as well as restoring confidence in vaccine administration for a COVID-19 free world.
id USP-23_d619dee0e08288b42c3fa3aa6b37fb60
oai_identifier_str oai:revistas.usp.br:article/192294
network_acronym_str USP-23
network_name_str Revista de Saúde Pública
repository_id_str
spelling SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?COVID-19, prevention & controlSARS-CoV-2, immunologyCOVID-19 VaccinesImmunogenicity, VaccineEmbolism and ThrombosisThe coronavirus disease 2019 (COVID-19) pandemic is significantly causing unprecedented clinical, socioeconomic, and public health challenges globally. The successful global administration of effective, safe and sustainable vaccine(s) is widely believed to be crucial in mitigating as well as preventing COVID-19. However, the rising cases of severe adverse events following immunization (AEFI) with COVID-19 vaccines including thrombosis, thrombocytopenia, and in some instances, death have created serious global concerns and could enormously contribute to vaccine hesitancy. Although the complete underlying pathophysiology and immunopathology of the COVID-19 vaccines related to AEFI, including thrombosis and/or anaphylaxis, are yet to be determined, exploring possible immuno-hypersensitivity could be crucial in the mechanisms associated with these reactions, thereby mitigating their occurrences as well as restoring confidence in vaccine administration for a COVID-19 free world.Universidade de São Paulo. Faculdade de Saúde Pública2021-10-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdftext/xmlhttps://www.revistas.usp.br/rsp/article/view/19229410.11606/s1518-8787.2021055003855Revista de Saúde Pública; Vol. 55 (2021); 70Revista de Saúde Pública; Vol. 55 (2021); 70Revista de Saúde Pública; v. 55 (2021); 701518-87870034-8910reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/rsp/article/view/192294/177180https://www.revistas.usp.br/rsp/article/view/192294/177179Copyright (c) 2021 Rine Christopher Reuben, Lillian Yami Adogohttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessReuben, Rine ChristopherAdogo, Lillian Yami2021-11-08T19:49:22Zoai:revistas.usp.br:article/192294Revistahttps://www.revistas.usp.br/rsp/indexONGhttps://www.revistas.usp.br/rsp/oairevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2021-11-08T19:49:22Revista de Saúde Pública - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?
title SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?
spellingShingle SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?
Reuben, Rine Christopher
COVID-19, prevention & control
SARS-CoV-2, immunology
COVID-19 Vaccines
Immunogenicity, Vaccine
Embolism and Thrombosis
title_short SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?
title_full SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?
title_fullStr SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?
title_full_unstemmed SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?
title_sort SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?
author Reuben, Rine Christopher
author_facet Reuben, Rine Christopher
Adogo, Lillian Yami
author_role author
author2 Adogo, Lillian Yami
author2_role author
dc.contributor.author.fl_str_mv Reuben, Rine Christopher
Adogo, Lillian Yami
dc.subject.por.fl_str_mv COVID-19, prevention & control
SARS-CoV-2, immunology
COVID-19 Vaccines
Immunogenicity, Vaccine
Embolism and Thrombosis
topic COVID-19, prevention & control
SARS-CoV-2, immunology
COVID-19 Vaccines
Immunogenicity, Vaccine
Embolism and Thrombosis
description The coronavirus disease 2019 (COVID-19) pandemic is significantly causing unprecedented clinical, socioeconomic, and public health challenges globally. The successful global administration of effective, safe and sustainable vaccine(s) is widely believed to be crucial in mitigating as well as preventing COVID-19. However, the rising cases of severe adverse events following immunization (AEFI) with COVID-19 vaccines including thrombosis, thrombocytopenia, and in some instances, death have created serious global concerns and could enormously contribute to vaccine hesitancy. Although the complete underlying pathophysiology and immunopathology of the COVID-19 vaccines related to AEFI, including thrombosis and/or anaphylaxis, are yet to be determined, exploring possible immuno-hypersensitivity could be crucial in the mechanisms associated with these reactions, thereby mitigating their occurrences as well as restoring confidence in vaccine administration for a COVID-19 free world.
publishDate 2021
dc.date.none.fl_str_mv 2021-10-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/rsp/article/view/192294
10.11606/s1518-8787.2021055003855
url https://www.revistas.usp.br/rsp/article/view/192294
identifier_str_mv 10.11606/s1518-8787.2021055003855
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/rsp/article/view/192294/177180
https://www.revistas.usp.br/rsp/article/view/192294/177179
dc.rights.driver.fl_str_mv Copyright (c) 2021 Rine Christopher Reuben, Lillian Yami Adogo
http://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Rine Christopher Reuben, Lillian Yami Adogo
http://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
text/xml
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Saúde Pública
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Saúde Pública
dc.source.none.fl_str_mv Revista de Saúde Pública; Vol. 55 (2021); 70
Revista de Saúde Pública; Vol. 55 (2021); 70
Revista de Saúde Pública; v. 55 (2021); 70
1518-8787
0034-8910
reponame:Revista de Saúde Pública
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Revista de Saúde Pública
collection Revista de Saúde Pública
repository.name.fl_str_mv Revista de Saúde Pública - Universidade de São Paulo (USP)
repository.mail.fl_str_mv revsp@org.usp.br||revsp1@usp.br
_version_ 1800221802410016768

Registros relacionados